Antibiotic treatment following surgical drainage of perianal abscess: a double-blind, placebo-controlled, randomized trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517233-40-00

Acronym

80-86600-98-19047

Enrollment

298

Registered

2024-11-11

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perianal abscess

Brief summary

Development of a perianal fistula within one year.

Detailed description

Quality of life at 12 months, Costs and cost-effectiveness, Need of repeated drainage, Recurrent abscess, Complications, Patient reported outcomes measures, Length of hospital stay, Readmissions, Time till return to work

Interventions

DRUGMetronidazol Aurobindo 500 mg

DRUGfilmomhulde tabletten

DRUGCiprofloxacine Teva 500 mg filmomhulde tabletten

DRUGPlacebo tablets

DRUGTiofarma B.V.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Development of a perianal fistula within one year.	—

Secondary

Measure	Time frame
Quality of life at 12 months, Costs and cost-effectiveness, Need of repeated drainage, Recurrent abscess, Complications, Patient reported outcomes measures, Length of hospital stay, Readmissions, Time till return to work	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026